Cargando…

Comparability of PD‐L1 immunohistochemistry assays for non‐small‐cell lung cancer: a systematic review

Programmed cell death ligand 1 (PD‐L1) immunohistochemistry is used to determine which patients with advanced non‐small‐cell lung cancer (NSCLC) respond best to treatment with PD‐L1 inhibitors. For each inhibitor, a unique immunohistochemical assay was developed. This systematic review gives an up‐t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koomen, Bregje M, Badrising, Sushil K, van den Heuvel, Michel M, Willems, Stefan M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318295/ https://www.ncbi.nlm.nih.gov/pubmed/31793055 http://dx.doi.org/10.1111/his.14040

Ejemplares similares

Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer
por: Phillips, Therese, et al.
Publicado: (2015)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer
por: Roach, Charlotte, et al.
Publicado: (2016)

The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer
por: Lee, Yong Seok, et al.
Publicado: (2021)

Nationwide differences in cytology fixation and processing methods and their impact on interlaboratory variation in PD-L1 positivity
por: Koomen, Bregje M., et al.
Publicado: (2022)

Standardization of PD-L1 immunohistochemistry
por: Martinez-Morilla, Sandra, et al.
Publicado: (2021)

Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in Treatment
por: Otten, Leila S., et al.
Publicado: (2023)

“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
por: Torlakovic, Emina, et al.
Publicado: (2019)

PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
por: Wu, Chiao-En, et al.
Publicado: (2020)

Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
por: Velcheti, Vamsidhar, et al.
Publicado: (2018)

False‐negative programmed death‐ligand 1 immunostaining in ethanol‐fixed endobronchial ultrasound‐guided transbronchial needle aspiration specimens of non‐small‐cell lung cancer patients
por: Koomen, Bregje M, et al.
Publicado: (2021)

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
por: Vennapusa, Bharathi, et al.
Publicado: (2019)

Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
por: Yeong, Joe, et al.
Publicado: (2022)

PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation
por: Keppens, Cleo, et al.
Publicado: (2020)

Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer
por: Xu, Haipeng, et al.
Publicado: (2017)

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
por: Hu, Weixian
Publicado: (2019)

PD-L1 testing by immunohistochemistry in immuno-oncology
por: Vranic, Semir, et al.
Publicado: (2023)

Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry
por: Huang, Richard S. P., et al.
Publicado: (2021)

PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes
por: Nesline, Mary K., et al.
Publicado: (2023)

Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
por: Noske, Aurelia, et al.
Publicado: (2021)

Quantitative Assessment of PD-L1 as an Analyte in Immunohistochemistry Diagnostic Assays using a Standardized Cell Line Tissue Microarray
por: Martinez-Morilla, Sandra, et al.
Publicado: (2019)

Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
por: Sharma, Meenal, et al.
Publicado: (2019)

PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2021)

Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay
por: Danziger, Natalie, et al.
Publicado: (2023)

Accurate expression of PD‐L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry
por: Shinchi, Yusuke, et al.
Publicado: (2019)

Harmonization across programmed death ligand 1 (PD‐L1) assays for lung cancer by immunohistochemistry using noncontact alternating current electric field mixing
por: Matsuo, Tsubasa, et al.
Publicado: (2021)

Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer
por: Theelen, Willemijn S. M. E., et al.
Publicado: (2019)

Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
por: Mino-Kenudson, Mari
Publicado: (2016)

Reliability of PD-L1 assays using small tissue samples compared with surgical specimens
por: Kim, Insu, et al.
Publicado: (2019)

Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma
por: Parra, Edwin R., et al.
Publicado: (2018)

Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR
por: Alwithenani, Akram, et al.
Publicado: (2021)

Formalin fixation for optimal concordance of programmed death‐ligand 1 immunostaining between cytologic and histologic specimens from patients with non–small cell lung cancer
por: Koomen, Bregje M., et al.
Publicado: (2020)

Development and applications of computer image analysis algorithms for scoring of PD-L1 immunohistochemistry
por: Inge, L.J., et al.
Publicado: (2020)

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
por: Zhou, Caicun, et al.
Publicado: (2023)

Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples
por: Soo, Ross A., et al.
Publicado: (2018)

Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer
por: Hout, David R., et al.
Publicado: (2017)

Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
por: Ilie, Marius, et al.
Publicado: (2017)

Development of a LAG-3 immunohistochemistry assay for melanoma
por: Johnson, Lori, et al.
Publicado: (2023)

Comparison of laboratory-developed test & validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma
por: Nambirajan, Aruna, et al.
Publicado: (2019)

Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
por: Ilie, Marius, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ovsooa4p0b7p9rrqm2eej9osa5